Amplifying Scientists
Scaling Scientific Excellence

Building Mass Spec AI Co-Scientists for biopharma

m/z  1,487.2
SYLVIA™ PETRA™ LAUNCHED ASMS 2026

AI is creating more complex drug candidates
than biopharma can efficiently characterize.
LiVeritas is breaking the characterization bottleneck.

MULTI-DIMENSIONAL VALUE CREATION

Scientific

Enhanced accuracy and precision

Workflow

Minimal repetitive load increases scientific judgment

Development

Accelerated characterization for immediate accomplishment

Regulatory

Traceable science with human oversight

Business & Enterprise

Scalable, standardized scientific capacity

Mass Spec AI Co-Scientists for biopharma

IN MARKET — LAUNCHED ASMS 2026

LiVeritas Sylvia™

Sequence Variant Analysis
Find What’s Different

Automates expert sequence-variant characterization workflows, helping scientists identify, evaluate, review, and interpret sequence variants from LC-MS data.

IN MARKET — LAUNCHED ASMS 2026

LiVeritas Petra™

Peptide Mapping and PTM Analysis
See What Changed

Automates peptide-level characterization and post-translational modification analysis.

EXPANDING PRODUCT SUITE — IN DEVELOPMENT

LiVeritas IrMA™ Intact Mass Analysis See the Whole Picture
LiVeritas Desmond™ Disulfide Characterization Confirm What Connects
LiVeritas Gian™ Glycan Analysis Map What Branches
LiVeritas INDIe™ Additional Characterization Turn Evidence Into Impact

FAQs

Learn more about LiVeritas, our AI Co-Scientists, and the science behind our platform.

LiVeritas Biosciences is a scientific intelligence technology company building Mass Spec AI Co-Scientists for biopharma drug candidate characterization. Our platform helps transform complex LC-MS analytical data into trusted, traceable scientific intelligence that supports drug development.

LiVeritas develops specialized AI Co-Scientists that automate expert protein characterization workflows using mass spectrometry. They help scientists process, organize, interpret, and review complex analytical data more efficiently while supporting higher-confidence scientific decision-making.

AI Co-Scientists are regulatory grade scientific execution software products designed around specific mass spectrometry workflows rather than general-purpose AI. Each Co-Scientist combines scientific data, validated workflows, domain knowledge, and traceable outputs to amplify scientists, not replace them.

LiVeritas currently offers LiVeritas Sylvia™ for Sequence Variant Analysis and LiVeritas Petra™ for Peptide Mapping and PTM Analysis. Additional AI Co-Scientists are in development to expand coverage across major protein characterization workflows.

LiVeritas combines real biopharma wet-lab experience, mass spectrometry expertise, validated scientific workflows, accumulated analytical knowledge, and specialized AI built specifically for regulated drug development. Our approach begins with scientific execution and creates reusable Scientific Intelligence across workflows and development programs.

News & publications

Explore the latest news, publications, and milestones from LiVeritas Biosciences.

/ 03
VIDEO LATEST

Philippine Consulate Visits LiVeritas Biosciences Laboratory

The Philippine Consulate General visits the LiVeritas Biosciences laboratory in San Francisco.

Watch video →
INTERVIEW NOV 22, 2024

Alum Lieza Danan: Immigrant, Entrepreneur, Survivor and Thriver

From selling candies in the Philippines to leading a biotech startup in California, Lieza Danan’s journey is one of resilience, vision, and scientific excellence. Now the CEO and co-founder of LiVeritas Biosciences, she’s transforming how drug candidates are tested and approved, bringing precision, purpose, and innovation to the forefront of biopharma.

Read story →
NEWS OCT 25, 2024

LiVeritas Won First Place in the Dream Bigger Pitch Competition

The Dream Bigger Challenge brought together over 100 Filipino founders, investors, and community champions from across North America to celebrate entrepreneurship and innovation.

Read story →
PRESS RELEASE JUL 19, 2023

LiVeritas Biosciences Introduces the LiLii™ Platform

An integrated laboratory ecosystem powered by AI. LiLii™ centralizes project management, CRM, document control, and analytics into a seamless interface, enabling drug developers to process data faster with greater accuracy and transparency.

Read story →
PROFILE DEC 19, 2022

LiVeritas CEO Lieza Danan Profiled in San Francisco Business Times

San Francisco Business Times profiles LiVeritas CEO Lieza Danan and her work building the company.

Read story →
COMPANY NEWS DEC 13, 2022

LiVeritas Biosciences Launches Manila Software Development Subsidiary

LiVeritas announces the launch of its Manila software development subsidiary.

Read story →
COMPANY NEWS MAR 22, 2022

LiVeritas Biosciences Launches Mass Spectrometry Outsourcing Solutions

LiVeritas announces mass spectrometry outsourcing solutions for biopharma and scientific characterization.

Read story →
CONTACT

Want to learn more about us? Let’s connect.

AI is creating more complex drug candidates than biopharma can efficiently characterize; LiVeritas is breaking the analytical bottleneck with a suite of Mass Spec AI Co-Scientists spanning protein characterization.

COMPANY
LiVeritas Biosciences, Inc.
LINKEDIN
linkedin.com/company/liveritas-biosciences
Thank you. We will contact you shortly.